Introduction

Proliferative Diabetic Retinopathy (PDR) remains a leading cause of preventable blindness among working-age adults worldwide. As the advanced stage of diabetic eye disease, PDR is defined by pathologic neovascularization on the retina and optic disc. While glycemic control and disease duration are well-established risk factors, the influence of patient age on both the severity of PDR and the response to treatment has emerged as a critical variable in clinical management. Age modifies the biology of angiogenesis, the integrity of the blood-retinal barrier, and the capacity for tissue repair, creating distinct phenotypes of PDR in younger versus older patients. Understanding these differences is essential for optimizing treatment strategies and improving visual outcomes across the age spectrum.

The underlying mechanism of PDR is driven by retinal ischemia, which triggers upregulation of vascular endothelial growth factor (VEGF). This growth factor stimulates the formation of fragile, leaky new vessels that are prone to hemorrhage and fibrosis. However, the angiogenic response is not uniform across ages. In younger patients, the retina exhibits a more robust VEGF production and a greater density of endothelial progenitor cells, leading to aggressive neovascularization. In contrast, older retinas show diminished angiogenic potential but increased oxidative stress and chronic low-grade inflammation, which can accelerate fibrosis and worsen tractional forces.

Age also alters the composition of the vitreous. In younger eyes, the vitreous is more gel-like and firmly attached to the retina, promoting the formation of neovascular fronds that extend into the vitreous cavity. In older eyes, vitreous liquefaction and posterior vitreous detachment are more common, which may reduce the scaffold for new vessel growth but also increase the risk of vitreous hemorrhage from bleeding sites. These age-dependent pathophysiologic differences have direct implications for disease presentation and therapeutic approaches.

How Age Influences PDR Severity

Younger Patients: A More Aggressive Disease Course

Younger individuals with PDR, particularly those with type 1 diabetes, often present with a rapidly progressive form of the disease. The neovascular response is florid, with large, elevated fibrovascular proliferations that can lead to recurrent vitreous hemorrhages and tractional retinal detachment within months. Data from longitudinal studies suggest that the risk of severe visual loss is significantly higher in patients under 40 years of age compared to older cohorts, even after adjusting for glycemic control. The presence of diabetic nephropathy or hypertension in younger patients further amplifies disease activity.

One reason for this aggressive behavior is the heightened VEGF expression in younger retinas, combined with a more active inflammatory milieu. Additionally, younger patients often have a longer life expectancy with diabetes, allowing cumulative damage to progress more rapidly. These factors demand earlier and more intensive intervention to prevent irreversible vision loss.

Older Patients: Slower Progression but Higher Complicating Factors

In patients over 60 years of age, PDR tends to follow a more indolent course. Neovascularization is often less exuberant, and the disease may remain quiescent for extended periods. However, the visual impact is frequently compounded by concurrent age-related ocular conditions such as cataract, age-related macular degeneration (AMD), and glaucoma. These comorbidities complicate both diagnosis and treatment. For example, the presence of dense cataract may obscure fundus view, delaying the detection of active neovascularization.

Furthermore, the retinal pigment epithelium (RPE) in older patients is less resilient to ischemia and metabolic stress, contributing to macular edema that is more resistant to therapy. Older patients also have higher rates of cardiovascular disease and diabetes-related microvascular damage in other organs, which can limit the feasibility of systemic treatments and increase the risk of surgical complications. The net effect is a disease that, while slower to progress, carries a substantial burden of functional impairment when it does become sight-threatening.

Laser Photocoagulation (PRP)

Panretinal photocoagulation (PRP) has been the cornerstone of PDR management for decades. However, its efficacy and adverse effects vary with age. In younger patients, PRP often effectively regresses neovascularization, but the acute inflammatory response can be more pronounced, leading to increased pain, transient macular edema, and anterior chamber inflammation. In older patients, the healing response after laser is slower, and the risk of choroidal neovascularization or development of exudative retinal detachment is slightly higher. Moreover, older eyes are more prone to laser-induced cataracts and the progressive loss of peripheral vision, which can be debilitating in an already vulnerable population.

Anti-VEGF Injections

Intravitreal anti-VEGF therapy (e.g., ranibizumab, aflibercept) has become first-line treatment for many patients with PDR, particularly those with associated diabetic macular edema (DME). Age significantly influences the pharmacokinetics and biologic response to these agents. Younger patients often require more frequent injections to maintain VEGF suppression due to their higher endogenous VEGF production. Studies have shown that young adults with PDR have a mean time to recurrence of neovascularization that is 2–4 weeks shorter than that of older adults.

In older patients, anti-VEGF therapy is at least as effective at inducing regression, but the incidence of ocular complications such as endophthalmitis, cataract progression, and intraocular inflammation increases with age due to decreased immune surveillance and barrier function. Additionally, older patients are more likely to have contraindications to therapy, such as recent thromboembolic events, which necessitate careful risk-benefit analysis. The addition of PRP to anti-VEGF in older patients may reduce the frequency of injections but must be weighed against the risk of visual field loss.

Vitrectomy

Pars plana vitrectomy (PPV) is indicated for non-clearing vitreous hemorrhage, tractional retinal detachment, or combined traction-rhegmatogenous detachment. The age of the patient is a major factor in surgical planning. In younger patients, the vitreous is more adhesive, making complete vitreous separation more challenging, which increases the risk of iatrogenic retinal breaks. However, younger eyes heal more robustly after surgery, with better visual potential and lower rates of postoperative complications like hypotony or choroidal effusion.

In older patients, vitreous liquefaction facilitates vitreous removal, but the reduced elasticity of the retina and the greater prevalence of epiretinal membranes make layer dissection more difficult. Postoperative macular edema is more common and persistent in elderly patients, and the visual recovery time is longer. The presence of cataract mandates combined phacovitrectomy in many older patients, adding another layer of complexity and potential for refractive error or capsular complications. Age-adjusted surgical protocols—such as using lower vacuum settings in older eyes and more complete shaving of the vitreous base in younger eyes—have been proposed to improve outcomes.

Special Considerations in Age-Based Management

Comorbidities

Age is a proxy for cumulative systemic disease burden. Hypertension, diabetic nephropathy, and dyslipidemia are more prevalent in older PDR patients and worsen the severity of retinal ischemia. Moreover, the use of anticoagulants or antiplatelet agents—common in older adults—increases the risk and severity of vitreous hemorrhage. Careful coordination with the patient’s primary care physician is essential to manage these risks without compromising treatment of PDR.

Medication Adherence and Monitoring

Younger patients often face challenges with treatment adherence due to occupational demands, transportation issues, or lack of disease perception. In contrast, older patients may have cognitive decline, visual impairment from cataract, or physical limitations that hinder timely follow-up. Screening intervals and injection schedules should be tailored accordingly. Using telemedicine for monitoring retinal status in older patients with limited mobility has shown promise in maintaining care continuity.

Emerging Therapies and Future Directions

Age-specific treatments are on the horizon. Novel anti-VEGF agents with extended durability (e.g., faricimab, brolucizumab) may reduce injection frequency, benefiting both young and old patients but especially the elderly, who are more prone to complications from repeated injections. Gene therapy approaches that stabilize the retinal microenvironment could be particularly advantageous for younger patients with a long life ahead. Additionally, intravitreal corticosteroid implants (e.g., dexamethasone, fluocinolone) are being explored for chronic DME in older patients with inadequate response to anti-VEGF, but their use is limited by high rates of cataract and glaucoma in the aging eye.

The integration of artificial intelligence for screening and personalized risk stratification may help identify age-specific thresholds for initiating treatment. Ongoing clinical trials are evaluating whether younger patients benefit from a treat-and-extend anti-VEGF regimen versus fixed monthly dosing, while elderly patients may do well with a wait-and-watch protocol for quiescent PDR.

Clinical Recommendations for Age-Based Management

Based on current evidence, a one-size-fits-all approach to PDR is inadequate. For patients younger than 40, consider early and frequent anti-VEGF injections combined with PRP as needed. Educate about the necessity of strict glycemic control and blood pressure management. Monitor closely for rapid progression and consider vitrectomy early for persistent vitreous hemorrhage.

For patients older than 65, prioritize safer interventions. Start with anti-VEGF monotherapy, using extended-interval dosing if possible. Add PRP only if neovascularization persists despite adequate VEGF suppression. Actively manage cataract and dry eye to improve visual quality. Consider surgical therapy after weighing cardiopulmonary risks and anticoagulant status. Encourage the use of home monitoring devices for intraocular pressure and vision self-assessment.

Conclusion

Age is a powerful modifier of the natural history, severity, and therapeutic response in proliferative diabetic retinopathy. Younger patients face a more aggressive disease that demands prompt, intensive treatment to preserve sight. Older patients experience a slower but more complicated course, burdened by comorbidities and reduced ocular resilience. Tailoring the treatment strategy to the patient’s age—and, more broadly, to their biologic age—can significantly improve visual outcomes and minimize treatment-related harms. Future research should continue to uncover the molecular mechanisms underlying age-related differences and develop therapies that address these specific needs.

References: National Eye Institute - Diabetic Retinopathy; Age as a Modifier of Treatment Response in PDR; AAO Preferred Practice Pattern – Diabetic Retinopathy.